What is VolitionRX Limited's market cap?

VolitionRX Limited (VNRX) has a market capitalization of $10.6M and trades on AMEX.

Who are VolitionRX Limited's competitors?

VolitionRX Limited's key competitors include Guardant Health, GRAIL Inc., Natera, and others. These companies compete in similar markets and product categories.

Who does VolitionRX Limited partner with?

VolitionRX Limited's notable partners include Antech Diagnostics, IDEXX Laboratories, Inc., Fujifilm Vet Systems Co. Ltd, and others.

What subsidiaries does VolitionRX Limited have?

VolitionRX Limited's subsidiaries include Singapore Volition Pte. Limited, Belgian Volition SRL, Volition America, Inc., and others.

Where is VolitionRX Limited headquartered?

VolitionRX Limited is headquartered in United States of America and employs approximately 110 people. It has been publicly traded since 2007.

VolitionRX Limited

VNRX

VolitionRx is a multi-national epigenetics company focused on developing simple, cost-effective blood tests for the early detection and monitoring of cancer and other life-altering diseases.

Market cap

$10.6M-85.5%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$985.1KMiss by $534.2K EPS-$0.97Miss by $0.27

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$442.0K

EPS estimate-$0.70

Competitors

By market cap

Natera, Inc.$37.0B+96.1%

Illumina$28.7B+64.8%

Guardant Health$19.3B+252%

GRAIL, Inc.$2.9B+108%

Personalis, Inc.$1.3B+135%

Nuvectis Pharma, Inc.$616.0M+288%

VolitionRX Limited$10.6M-86.0%

ONC

Onconetix, Inc.$3.0M+55.2%

By revenue growth

Guardant Health+39.6%

Natera, Inc.+36.6%

GRAIL, Inc.+19.4%

Illumina+1.3%

Personalis, Inc.-24.7%

By net margin

Illumina19.42%+41.7pp

Natera, Inc.-14.61%-3.2pp

Guardant Health-40.1%+13.7pp

Personalis, Inc.-148.11%-50.0pp

GRAIL, Inc.-253.22%+1,211pp

Profile

VolitionRx is a multi-national epigenetics company focused on developing simple, cost-effective blood tests for the early detection and monitoring of cancer and other life-altering diseases. The company leverages its proprietary Nucleosomics technology to identify chromosomal structures and biomarkers in both human and animal health. Its platform-agnostic solutions are designed to integrate into existing clinical workflows, ranging from central laboratories to point-of-care settings.

Competitive position

VolitionRx positions itself as a low-cost, platform-agnostic alternative to expensive sequencing-based liquid biopsies by focusing on nucleosome quantification.

GeographiesUnited States, Europe, Asia

Customer segmentsVeterinary Professionals, Healthcare Providers, Pharmaceutical Developers

Business modelIP Licensing, Product Manufacturing, Diagnostic Services

SuppliersAntibody suppliers, Third-party ELISA kit manufacturers, Academic research partners

CustomersReference laboratories, Hospitals, Veterinary clinics, Pharmaceutical R&D departments

CountryUnited States of America

Listed2007

Employees110.0

CEOCameron Reynolds

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitevolition.com

FilingsSEC EDGAR

Questions, answered.

What is VolitionRX Limited's market cap?: VolitionRX Limited (VNRX) has a market capitalization of $10.6M and trades on AMEX.
Who are VolitionRX Limited's competitors?: VolitionRX Limited's key competitors include Guardant Health, GRAIL Inc., Natera, and others. These companies compete in similar markets and product categories.
Who does VolitionRX Limited partner with?: VolitionRX Limited's notable partners include Antech Diagnostics, IDEXX Laboratories, Inc., Fujifilm Vet Systems Co. Ltd, and others.
What subsidiaries does VolitionRX Limited have?: VolitionRX Limited's subsidiaries include Singapore Volition Pte. Limited, Belgian Volition SRL, Volition America, Inc., and others.
Where is VolitionRX Limited headquartered?: VolitionRX Limited is headquartered in United States of America and employs approximately 110 people. It has been publicly traded since 2007.